Tom Seijkens

3.3k total citations · 1 hit paper
52 papers, 1.9k citations indexed

About

Tom Seijkens is a scholar working on Immunology, Oncology and Immunology and Allergy. According to data from OpenAlex, Tom Seijkens has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Immunology, 22 papers in Oncology and 12 papers in Immunology and Allergy. Recurrent topics in Tom Seijkens's work include Atherosclerosis and Cardiovascular Diseases (24 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cell Adhesion Molecules Research (12 papers). Tom Seijkens is often cited by papers focused on Atherosclerosis and Cardiovascular Diseases (24 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cell Adhesion Molecules Research (12 papers). Tom Seijkens collaborates with scholars based in Netherlands, Germany and United States. Tom Seijkens's co-authors include Esther Lutgens, Pascal Kusters, Linda Beckers, Menno P.J. de Winther, Dirk Lievens, Christian Weber, Mat J.A.P. Daemen, Louis Boon, Erik A.L. Biessen and Erwin Wijnands and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and Circulation Research.

In The Last Decade

Tom Seijkens

49 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma

2024 57 citations Sebastian Klobuch, Tom Seijkens et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Seijkens Netherlands	24	1.1k	471	444	342	318	52	1.9k
Giovanni Maria Garbarino Italy	28	843 0.8×	461 1.0×	855 1.9×	213 0.6×	171 0.5×	74	2.7k
Louisa M.S. Gerhardt United States	12	957 0.9×	174 0.4×	677 1.5×	316 0.9×	371 1.2×	19	1.8k
Roslynn A. Stirzaker United States	8	848 0.8×	220 0.5×	555 1.3×	475 1.4×	263 0.8×	8	1.8k
Christoph Renné Germany	20	738 0.7×	522 1.1×	508 1.1×	139 0.4×	122 0.4×	29	2.1k
Matthias Canault France	21	445 0.4×	209 0.4×	515 1.2×	199 0.6×	232 0.7×	42	1.6k
Jamila Khallou‐Laschet France	24	1.0k 0.9×	164 0.3×	428 1.0×	321 0.9×	138 0.4×	38	1.7k
Dick Wågsäter Sweden	31	949 0.9×	624 1.3×	930 2.1×	428 1.3×	433 1.4×	87	2.9k
Holger Winkels Germany	20	1.9k 1.8×	197 0.4×	1.1k 2.4×	522 1.5×	268 0.8×	46	2.7k
Olivier Harari United Kingdom	20	839 0.8×	191 0.4×	428 1.0×	107 0.3×	135 0.4×	37	1.9k
Can Shi China	23	690 0.7×	160 0.3×	947 2.1×	169 0.5×	251 0.8×	43	2.0k

Countries citing papers authored by Tom Seijkens

Since Specialization

Citations

This map shows the geographic impact of Tom Seijkens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Seijkens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Seijkens more than expected).

Fields of papers citing papers by Tom Seijkens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Seijkens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Seijkens. The network helps show where Tom Seijkens may publish in the future.

Co-authorship network of co-authors of Tom Seijkens

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Seijkens. A scholar is included among the top collaborators of Tom Seijkens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Seijkens. Tom Seijkens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seijkens, Tom, et al.. (2025). Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors. Nature Reviews Nephrology. 21(10). 687–701.

Tan, Yadi, et al.. (2025). Advances in TIL therapy: Expanding the horizons beyond melanoma. Med. 6(8). 100702–100702. 1 indexed citations

Seijkens, Tom, et al.. (2024). 1118P Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial. Annals of Oncology. 35. S737–S738.

Borgers, Jessica S.W., Johannes V. van Thienen, Sebastian Klobuch, et al.. (2024). Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned. ESMO Open. 9(2). 102383–102383. 6 indexed citations

Klobuch, Sebastian, Tom Seijkens, Ton N. Schumacher, & John B.A.G. Haanen. (2024). Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nature Reviews Clinical Oncology. 21(3). 173–184. 57 indexed citations breakdown →

Toom, Myrthe den, Linda Beckers, Cindy P. A. A. van Roomen, et al.. (2024). T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis, but increases plaque T cell infiltration and systemic T cell activation. Frontiers in Immunology. 15. 1297893–1297893. 3 indexed citations

Kapiteijn, Ellen, Petra Dibbets‐Schneider, Floris H. P. van Velden, et al.. (2024). Arterial inflammation on [18F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I. Atherosclerosis. 398. 118595–118595. 2 indexed citations

Klobuch, Sebastian, Tom Seijkens, & John B.A.G. Haanen. (2023). The emerging role for CAR T cells in solid tumor oncology. Chinese Clinical Oncology. 12(2). 19–19. 6 indexed citations

Poels, Kikkie, Mandy M. T. van Leent, Myrthe E. Reiche, et al.. (2020). Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. Cells. 9(9). 1987–1987. 69 indexed citations

10.

Bosch, Lena, et al.. (2020). The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease. Journal of Cardiovascular Translational Research. 14(1). 13–22. 48 indexed citations

11.

Poels, Kikkie, et al.. (2020). E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 7. 106–106. 9 indexed citations

12.

Poels, Kikkie, Johan G. Schnitzler, Farahnaz Waissi, et al.. (2020). Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. Frontiers in Cell and Developmental Biology. 8. 581641–581641. 48 indexed citations

13.

Bosch, Lena, Tom Seijkens, Claudia M. van Tiel, et al.. (2018). Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure. International Journal of Cardiology. 279. 141–144. 15 indexed citations

14.

Aarts, Suzanne A. B. M., Tom Seijkens, Pascal Kusters, et al.. (2017). Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. Journal of Neuroinflammation. 14(1). 105–105. 33 indexed citations

15.

Kusters, Pascal, Tom Seijkens, Christina Bürger, et al.. (2017). Constitutive CD40 Signaling in Dendritic Cells Limits Atherosclerosis by Provoking Inflammatory Bowel Disease and Ensuing Cholesterol Malabsorption. American Journal Of Pathology. 187(12). 2912–2919. 10 indexed citations

16.

Aarts, Suzanne A. B. M., et al.. (2017). The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Frontiers in Immunology. 8. 1791–1791. 57 indexed citations

17.

Valk, Fleur M. van der, Dominik M. Schulte, Svenja Meiler, et al.. (2016). Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine Nanotechnology Biology and Medicine. 12(6). 1463–1470. 31 indexed citations

18.

Berg, Susan M. van den, Tom Seijkens, Pascal Kusters, et al.. (2014). Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. International Journal of Obesity. 39(5). 782–790. 45 indexed citations

19.

Seijkens, Tom, David Engel, Marc Tjwa, & Esther Lutgens. (2010). The role of CD154 in haematopoietic development. Thrombosis and Haemostasis. 104(10). 639–701. 21 indexed citations

20.

Engel, David, Tom Seijkens, Marjorie Poggi, et al.. (2009). The immunobiology of CD154–CD40–TRAF interactions in atherosclerosis. Seminars in Immunology. 21(5). 308–312. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact